Clinical Trial Update: Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial assessing the combination of ensartinib and durvalumab in ALK-rearranged non-small cell lung cancer has completed with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Ensartinib (Ensartinib)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Non-small Cell Lung Cancer, Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-08-21